X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SUN PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SUN PHARMA FRESENIUS KABI ONCO./
SUN PHARMA
 
P/E (TTM) x 22.1 25.4 87.1% View Chart
P/BV x 3.1 3.7 83.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 FRESENIUS KABI ONCO.   SUN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SUN PHARMA
Mar-17
FRESENIUS KABI ONCO./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs176842 20.9%   
Low Rs79572 13.7%   
Sales per share (Unadj.) Rs37.7131.6 28.6%  
Earnings per share (Unadj.) Rs5.132.7 15.6%  
Cash flow per share (Unadj.) Rs6.738.0 17.7%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs42.5152.7 27.9%  
Shares outstanding (eoy) m158.232,399.26 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.4 62.8%   
Avg P/E ratio x25.021.6 115.5%  
P/CF ratio (eoy) x18.918.6 101.6%  
Price / Book Value ratio x3.04.6 64.6%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m20,1351,696,877 1.2%   
No. of employees `0001.217.5 6.6%   
Total wages/salary Rs m70349,023 1.4%   
Avg. sales/employee Rs Th5,176.218,028.3 28.7%   
Avg. wages/employee Rs Th610.42,798.8 21.8%   
Avg. net profit/employee Rs Th699.64,479.5 15.6%   
INCOME DATA
Net Sales Rs m5,963315,784 1.9%  
Other income Rs m186,232 0.3%   
Total revenues Rs m5,981322,016 1.9%   
Gross profit Rs m1,430100,893 1.4%  
Depreciation Rs m25812,648 2.0%   
Interest Rs m-263,998 -0.7%   
Profit before tax Rs m1,21690,479 1.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34212,116 2.8%   
Profit after tax Rs m80678,462 1.0%  
Gross profit margin %24.031.9 75.1%  
Effective tax rate %28.113.4 210.1%   
Net profit margin %13.524.8 54.4%  
BALANCE SHEET DATA
Current assets Rs m5,102329,537 1.5%   
Current liabilities Rs m2,385178,870 1.3%   
Net working cap to sales %45.647.7 95.5%  
Current ratio x2.11.8 116.1%  
Inventory Days Days15079 190.0%  
Debtors Days Days11383 136.1%  
Net fixed assets Rs m5,148204,766 2.5%   
Share capital Rs m1582,399 6.6%   
"Free" reserves Rs m6,556363,997 1.8%   
Net worth Rs m6,732366,397 1.8%   
Long term debt Rs m95214,361 6.6%   
Total assets Rs m10,388614,102 1.7%  
Interest coverage x-45.823.6 -193.7%   
Debt to equity ratio x0.10 360.9%  
Sales to assets ratio x0.60.5 111.6%   
Return on assets %7.513.4 55.9%  
Return on equity %12.021.4 55.9%  
Return on capital %14.624.8 58.8%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29844,118 12.0%   
Fx outflow Rs m1,77224,484 7.2%   
Net fx Rs m3,52519,634 18.0%   
CASH FLOW
From Operations Rs m1,27470,822 1.8%  
From Investments Rs m-1,204-42,216 2.9%  
From Financial Activity Rs m-196-22,854 0.9%  
Net Cashflow Rs m-1266,107 -2.1%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 9.6 23.0 41.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   42,599 133,026 32.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS